← Back
X4 Pharmaceuticals
XFOR · listed on Nasdaq · worth $319.75 million
$3.01
−0.33% on Oct 21
One insider buy in the last year, $250K in all. None in the last two weeks.
Green dot = an insider bought red = sold◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
57.2M shares
58% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, one insider bought X4 Pharmaceuticals stock and one insider sold. None of the 2 sales is marked on its filing as planned in advance; all by company executives.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
Executive Chairman
Adam R. Craig
Bought $250K on Oct 23, 2025 — 86,206 shares at $2.90, 23% of what they now own.
1 of 1 earlier purchase did better than the S&P 500
Planned sales
Form 144 notices filed for X4 Pharmaceuticals in recent months, beside the Form 4 sales reported after each. A notice says a person intends to sell; it is not a sale.
CFO David Kirske filed to sell 11,767 shares on 1 Oct; sold 11,767 by 1 OctNotice on SEC.gov
Chair Adam R. Craig filed to sell 47,436 shares on 13 Aug; no sale reported yetNotice on SEC.gov
President John Volpone filed to sell 24,576 shares on 13 Aug; no sale reported yetNotice on SEC.gov
Big investors
People and funds that reported owning 5% or more of X4 Pharmaceuticals, newest first.
Filed by someone who owns 5% or more and does not plan to influence the company. · updateFMR LLC4.6%Oct 7
Filed by someone who owns 5% or more and does not plan to influence the company.Venrock Healthcare Capital Partners III5.6%Sep 21
Filed by someone who owns 5% or more and does not plan to influence the company. · updatePerceptive Advisors LLC8.1%Aug 14
All reports
Every insider trade and SEC report we hold for X4 Pharmaceuticals.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Oct 27, 2025BoughtAdam R. CraigOct 27, 2025 · Traded Oct 23, 2025 · Executive Chairman+23%86,206 @ $2.90$250K
Analysts, earnings and news
Analysts' price target
$11.75 average
4 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
4 of 4 quarters above
Q1 '26−$0.16 a share+$0.04
Q4 '25−$0.22 a share+$0.13
Q3 '25−$0.69 a share+$0.15
Q2 '25−$3.47 a share+$0.87